Quantitative analysis of polysorbate 20/80 in biopharmaceuticals by HPLC-MS
Why analyze polysorbate 20/80 in biopharmaceutical products using HPLC-MS?
Polysorbate 20 and polysorbate 80 are essential excipients in biopharmaceutical formulations. Their main role is to ensure protein stability by reducing the risk of denaturation and aggregation. However, their degradation, caused by oxidative, hydrolytic, or enzymatic processes, can affect the efficacy of drugs and even compromise their safety.
Faced with these challenges, the HPLC-MS (High Performance Liquid Chromatography coupled with Mass Spectrometry) method is a fast and effective approach for accurately analyzing and quantifying polysorbates 20/80 in complex environments such as protein solutions.
An effective "one-pot" analysis method
The concept behind this method, which refers to a process whereby all the necessary steps of an analysis or synthesis are carried out in a single container, is based on two principles: the hydrolysis of esters of polysorbate fatty acids and the rapid methylation of free fatty acids to improve their detection. Thanks to a “one-pot” process, the sample preparation step is simplified, facilitating its integration into formulation, development, and quality control (QC) environments.
The analytical approach is as follows:
- Chromatographic separation: using a high-performance C8 HPLC column.
- High-sensitivity MS detection: for accurate identification of methylated fatty acids present in polysorbates.
The method demonstrates remarkable sensitivity, achieving detection levels below ppm. It thus allows precise quantification of polysorbate constituents, even in complex matrices.
The advantages of the HPLC-MS method
Increased sensitivity and specificity
Unlike traditional approaches such as ELSD or CAD, detection by mass spectrometry (MS) offers better resolution of the components of polysorbate. It also provides increased sensitivity, making it possible to detect subtle changes in concentrations and accurately identify the fatty acids that make up polysorbates (e.g., lauric for PS-20 and oleic for PS-80).
Deployment and scalability
This method is universally applicable for the analysis of polysorbates 20 and 80, regardless of the type of biopharmaceutical product. It is easily deployable in quality control and development laboratories, ensuring flexibility and efficiency for analytical teams.
Versatility
Universal applicability for complex matrices (protein solutions, finished products).
Practical applications in the biopharmaceutical environment
Formulation development: precise monitoring of polysorbate concentrations to optimize protein stability
Stability studies: detection of degradation products to anticipate impacts on drug efficacy
Quality control (QC): monitoring polysorbates in finished products to ensure compliance
In conclusion
Quantitative analysis of polysorbates 20/80 by HPLC-MS is a reference method in the biopharmaceutical sector. Thanks to its sensitivity, specificity, and ability to process complex matrices, it meets the growing demands for drug quality and safety. This technology is an essential tool for analytical and development laboratories in the context of regulatory compliance (EMA, FDA) and technical performance.
Frequently asked questions
Why quantify polysorbates 20 and 80 in a biopharmaceutical formulation?
These surfactants help stabilise protein formulations, particularly by limiting certain interactions at interfaces. Their concentration and changes over time can inform formulation and stability studies. The assay must be interpreted alongside other product characteristics: an acceptable polysorbate concentration alone does not establish the medicine’s stability or safety.
What does the one-pot preparation described for polysorbate HPLC-MS analysis measure?
The preparation described hydrolyses polysorbate esters and then methylates the released fatty acids, which serve as analytical markers. It therefore does not directly measure every intact species in the mixture. Converting these markers into polysorbate concentration depends on calibration, product composition and control of the preparation steps.
Can fatty acid measurement distinguish every polysorbate degradation mechanism?
A global measurement after hydrolysis cannot describe all the original species or their transformations. Fatty acids already present in free form, other excipients or oxidation products may require additional investigation. The analytical programme must distinguish the intended assay from the study of degradation pathways, depending on the formulation and the question being addressed.
Can a polysorbate HPLC-MS method be used without adaptation for any protein solution?
The method must be verified in the relevant matrix and concentration range. Extraction, reaction yield, interferences and matrix effects can alter the response. Specificity, recovery, precision and stability studies help assess fitness for purpose; performance reported for one formulation does not automatically apply to another. Explore HPLC-MS analysis.
How should polysorbate concentrations in two biopharmaceutical batches be compared?
Analyse both batches using a common protocol, documented references and storage conditions. Formulation, polysorbate origin and the calculation basis must be comparable. Any difference should be interpreted alongside uncertainty and stability data, rather than immediately attributed to a single degradation mechanism.